Single-Center Outcomes of WATCHMAN™ Implantation with Comparison to Oral Anticoagulant and Dual Antiplatelet Therapy

Background The WATCHMAN™ device is a Food and Drug Administration (FDA)-approved device that reduces the risk of stroke from atrial fibrillation (AF) in those who have a contraindication to taking oral anticoagulation. A key aspect of this device implantation is the choice of medical therapy in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Demiraj, Francis, Benrubi, Michael S, Babici, Denis, Muharremi, Eti, Pachon, Ronald, Osman, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659817/
https://www.ncbi.nlm.nih.gov/pubmed/38021921
http://dx.doi.org/10.7759/cureus.47444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659817/
https://www.ncbi.nlm.nih.gov/pubmed/38021921
http://dx.doi.org/10.7759/cureus.47444

Ejemplares similares